Screener
Novanta NOVT Medical Solutions — Research And Development Expense
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novanta in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Novanta’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335404
| Line item | Three Months Ended July 3, 2026 / Automation Enabling Technologies | Three Months Ended July 3, 2026 / Medical Solutions | Three Months Ended July 3, 2026 / Total | Six Months Ended July 3, 2026 / Automation Enabling Technologies | Six Months Ended July 3, 2026 / Medical Solutions | Six Months Ended July 3, 2026 / Total |
|---|---|---|---|---|---|---|
| Cost of revenue | 63,419 | 76,714 | 130,707 | 148,443 | ||
| Amortization of purchased intangible assets | 1,200 | 2,555 | 2,400 | 5,114 | ||
| Segment gross profit | 71,596 | 50,323 | 121,919 | 134,352 | 102,498 | 236,850 |
| Research and development and engineering | 9,496 | 14,667 | 18,528 | 28,915 | ||
| Selling, general and administrative | 20,784 | 16,585 | 40,673 | 32,891 | ||
| Amortization of purchased intangible assets | 2,704 | 3,711 | 4,823 | 7,366 | ||
| Restructuring, acquisition, and related costs | 2,020 | 1,753 | 2,583 | 2,993 | ||
| Segment operating income | 36,592 | 13,607 | 50,199 | 67,745 | 30,333 | 98,078 |
Item 1. Financial Statements
FAQ
- What is Novanta's medical solutions — research and development expense?
- Novanta (NOVT) reported medical solutions — research and development expense of $14.67M in Q2 2026.
- How has Novanta's medical solutions — research and development expense changed year-over-year?
- Novanta's medical solutions — research and development expense decreased by 9.3% year-over-year, from $16.17M to $14.67M.
- What is the long-term trend for Novanta's medical solutions — research and development expense?
- Over 3 years (2022 to 2025), Novanta's medical solutions — research and development expense has grown at a 13.0% compound annual growth rate (CAGR), from $40.42M to $58.34M.
- What does medical solutions — research and development expense mean?
- Costs incurred by the Medical Solutions segment to develop new products, improve existing technologies, and advance scientific capabilities. This investment is critical for maintaining long-term competitive advantage and innovation within the medical device or solutions market.
Ask your AI about Novanta's medical solutions — research and development expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude